Vaccinated monkeys have developed "long-term"
immunity to the Ebola virus, raising a prospect of successful human trials, say
scientists.
The experiments by the US National Institutes of Health showed immunity could last at least 10 months.
Human trials of the vaccine started this week in the US and will extend to the UK and Africa.
The World Health Organization says more than 2,000 people have now died in the outbreak in West Africa.
Several experimental treatments are now being considered to help contain the spread of Ebola.
This includes a vaccine being developed by the US National Institute of Allergy and Infectious Diseases and pharmaceutical company GlaxoSmithKline.
It uses a genetically modified chimp virus containing components of two species of Ebola - Zaire, which is currently circulating in West Africa, and the common Sudan species.
The viral vaccine does not replicate inside the body, but it is hoped the immune system will react to the Ebola component of the vaccine and develop immunity.
The experiments by the US National Institutes of Health showed immunity could last at least 10 months.
Human trials of the vaccine started this week in the US and will extend to the UK and Africa.
The World Health Organization says more than 2,000 people have now died in the outbreak in West Africa.
Several experimental treatments are now being considered to help contain the spread of Ebola.
This includes a vaccine being developed by the US National Institute of Allergy and Infectious Diseases and pharmaceutical company GlaxoSmithKline.
It uses a genetically modified chimp virus containing components of two species of Ebola - Zaire, which is currently circulating in West Africa, and the common Sudan species.
The viral vaccine does not replicate inside the body, but it is hoped the immune system will react to the Ebola component of the vaccine and develop immunity.
No comments:
Post a Comment